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Abstract
Recent studies suggest that M. tuberculosis lineage and host genetics interact to impact how active tuberculosis presents clinically.
We determined the phylogenetic lineages of M. tuberculosis isolates from participants enrolled in the Tuberculosis Trials
Consortium Study 28, conducted in Brazil, Canada, South Africa, Spain, Uganda and the United States, and secondarily explored
the relationship between lineage, clinical presentation and response to treatment. Large sequence polymorphisms and single
nucleotide polymorphisms were analyzed to determine lineage and sublineage of isolates. Of 306 isolates genotyped, 246 (80.4%)
belonged to the Euro-American lineage, with sublineage 724 predominating at African sites (99/192, 51.5%), and the Euro-
American strains other than 724 predominating at non-African sites (89/114, 78.1%). Uneven distribution of lineages across regions
limited our ability to discern significant associations, nonetheless, in univariate analyses, Euro-American sublineage 724 was
associated with more severe disease at baseline, and along with the East Asian lineage was associated with lower bacteriologic
conversion after 8 weeks of treatment. Disease presentation and response to drug treatment varied by lineage, but these
associations were no longer statistically significant after adjustment for other variables associated with week-8 culture status.
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Introduction
Mycobacterium tuberculosis is genetically more diverse than previ-
ously believed [1]. With the availability of whole genome sequences
of several clinical isolates [2,3,4], the genetic diversity of M.
tuberculosis has been chronicled in the form of insertions, deletions,
and single nucleotide polymorphisms (SNP). These polymorphisms
have enabled researchers to genotype and classify clinical strains of
M. tuberculosis into different groups. Recently, a group of insertions/
deletions (also known as region of difference or RD) that are unique
event polymorphisms and define a robust phylogeny were
described. Based on this phylogeny, six lineages of M. tuberculosis
have been defined [5]. Studies suggest that certain lineages
preferentially cause active tuberculosis amongst human populations
with distinct genetic ancestry [6,7]. Some M. tuberculosis strains have
been associated with increased transmission and some are reported
to induce stronger host inflammatory responses when compared
with the laboratory strain H37Rv [8,9,10]. Given the diversity in
insertions, deletions and SNPs seen in M. tuberculosis, it is plausible
that the genetics of the pathogen play a role not only in the natural
history of tuberculosis infection and disease [11], but also in
presentation of disease and response to treatment.
In this study, we sought to determine the M. tuberculosis lineages
of isolates from pulmonary tuberculosis patients from four
continents who were enrolled in a clinical trial, USPHS
Tuberculosis Trials Consortium (TBTC) Study 28, a phase 2 trial
designed to compare the antimicrobial activity and safety of
moxifloxacin versus isoniazid when used in combination with
rifampin, pyrazinamide, and ethambutol during the first 8 weeks
of therapy for smear positive, culture confirmed, drug-susceptible
pulmonary tuberculosis [12]. Secondarily, we explore in a limited
analysis the influence of lineage and sublineage on presentation of
disease and response to treatment using the trial’s standardized
microbiologic endpoints.
Materials and Methods
Ethics Statement
The parent TBTC clinical trial, Study 28, was approved by
both CDC and local institutional review boards. Written informed
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institutional review board at UCSF approved this ancillary study
to determine the lineage of M. tuberculosis and to analyze its
influence on presentation of disease and response to treatment.
Study Population and Setting
TBTC Study 28 was a randomized, placebo-controlled, double-
blind, phase 2 clinical trial to evaluate the antimicrobial activity
and safety of moxifloxacin substituted for isoniazid during the first
2 months (intensive phase) of combination treatment for smear
positive, culture-confirmed, drug-susceptible pulmonary tubercu-
losis. Sputum culture status on both liquid and solid media at the
completion of 8 weeks of treatment was the primary endpoint and
was used as a surrogate endpoint for treatment efficacy. Adults
were enrolled from February 2006 through March 2007 at 26
sites, including 21 sites in the United States and one site each in
Brazil, Canada and Spain (collectively categorized as non-African
region sites for this analysis) and one site each in South Africa and
Uganda (categorized as African region sites). All tuberculosis
treatment was administered 5 days/week for 8 weeks and directly
observed. All participants underwent HIV testing. Sputum
cultures were done biweekly on both solid and liquid media
during the first eight weeks of treatment. Overall, 92% of liquid
cultures were performed in a BACTEC MGIT 960 system
(Becton, Dickinson and Co., Franklin Lakes, NJ) or a BACTEC
460TB system (Becton, Dickinson and Co.). Types of solid
medium used by local laboratories included Lowenstein-Jensen,
Middlebrook 7H10, and Middlebrook 7H11. M. tuberculosis isolates
underwent confirmatory drug-susceptibility testing at the Centers
for Disease Control and Prevention (CDC) using the indirect agar
proportion method for isoniazid, rifampin, ethambutol, and
fluoroquinolones (ofloxacin and ciprofloxacin critical concentra-
tions of 2mg/ml); MGIT 960 medium was used for pyrazinamide
susceptibility testing. In Study 28, no significant difference was
found in the rate of bacteriologic culture conversion after 8 weeks
of treatment between patients taking either the moxifloxacin or
isoniazid containing drug regimens [12]. However, patients
enrolled at African sites were significantly more likely to remain
sputum culture positive after 8 weeks of treatment than patients
enrolled at non-African sites, even after adjustment for pulmonary
cavitation, HIV infection, and history of treatment in the days
prior to study enrollment.
Selection of participants and Isolates
As in the primary analysis of Study 28, we included patient data
and M. tuberculosis isolates from all 328 protocol correct
participants (as defined by adherence to study treatment and
report of all biweekly culture results) in the current study.
Genotyping techniques
Large sequence polymorphism (LSP) and single nucleotide
polymorphism-based typing for the determination of the lineage
and sublineage were performed as previously described [7,13].
The MTB Research Laboratory at the University of California,
San Francisco performed all genotyping and was blinded to the
study site from which the isolates originated. Consequently, a
systematic algorithm was applied to all isolates received from the
CDC (Figure 1). Briefly, the katG 463 codon was analyzed using
real time PCR. If the codon was defined as cgg [14] the strain was
considered to belong to the Euro-American lineage. Because the
Euro-American sublineage 724 has been described as predomi-
nant in Uganda [15] and Euro-American sublineage 761
predominant in South Africa [7], we next screened for these two
sublineages. If the katG 463 codon was defined as ctg, we
proceeded to screen for LSPs that define the East-African-Indian,
Indo-Oceanic, East Asian, West African 1 and West African 2
lineages. PCR and/or multiplex real-time PCR (Applied Biosys-
tems, Foster City, CA and Stratagene, La Jolla CA, USA) were
used to determine the presence or absence of the RDs, using
primers previously published [13].
Statistical Analysis
The number of participants and isolates included was
determined from the parent clinical trial. Race/ethnicity was
determined by site staff using categories defined in the United
States tuberculosis surveillance system. The definitions and
primary objectives of this study were formulated prior to data
analysis. All statistical analysis was done using SAS v.9.2 (Cary,
NC). The initial analysis included describing the observed
genotypes and their clinical presentation, stratified by region of
enrollment (Africa versus non-Africa). Analysis of deviance
(ANODEV), and Pearson’s chi-square or Fisher’s exact tests for
differences among the lineages were used, as appropriate.
Subsequent analyses were directed at evaluating the influence of
M. tuberculosis lineage on treatment response as measured by 8-
week culture status. Associations between lineage and 8-week
culture conversion were evaluated using univariate logistic
regression analysis, excluding West African lineages due to small
numbers. Univariate analyses stratified by region of enrollment
and presence of baseline cavitation were done to address potential
confounding. Associations with 8-week culture conversion were
adjusted in multivariate logistic regression models for factors found
to be significant in the parent clinical trial.
Results
Distribution of lineages of M. tuberculosis
M. tuberculosis lineage/sublineage was successfully determined in
306 (93%) of 328 protocol correct participants enrolled in Study
28, with 192 (63%) enrolled at African sites [168 (88%) from
Kampala, Uganda and 24 (12%) from Durban, South Africa] and
114 (37%) enrolled at Non-African sites. Genotype information
was not available in 22/328 (9.2%) participants either because
repeated attempts to re-grow the isolates were unsuccessful (n=20)
or the genotyping suggested mixed infection with more than one
lineage of M. tuberculosis (n=2). Of the 306 isolates successfully
genotyped, 246 (80%) belonged to the Euro-American lineage,
101 of which were sublineage 724, and 145 isolates were Euro-
American other than sublineage 724 (which included 3 isolates
genotyped as Euro-American sublineage 761). Other lineages
observed in this cohort included East-African-Indian (26, 8.5%),
East Asian (22, 7.2%), Indo-Oceanic (11, 3.6%), and West African
1 (1 0.3%) and their specific geographic distribution is shown in
Table 1.
The distribution of M. tuberculosis lineages and sublineages
varied by geographic region. Euro-American sublineage 724
predominated among African region participants (99/192,
52%), whereas Euro-American other than 724 predominated
among non-African region participants (89/114, 78%). The
majority of Euro-American 724 (99/101, 98%) and East-
African-Indian (24/26, 92%) lineage isolates were identified in
African region participants. In contrast, the majority of Indo-
Oceanic (10/11, 91%), Euro-American other than 724 (89/145,
61%), and West African 1 (1/1, 100%) were identified in non-
African region participants (Table 1). East Asian lineage was
found in equal frequency by region of enrollment, but in Africa,
it was isolated primarily from participants enrolled in Durban,
South Africa.
M. tb Lineage Variability
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Disease characteristics including cavitation on baseline chest
radiograph, extensive lung involvement, high bacillary load on
baseline sputum smear (defined as 3+/4+ scoring of acid-fast
bacilli in the smear), and presence of cough or fever at time of
presentation were analyzed to determine if any association existed
with lineage of M. tuberculosis. Overall, bacillary load on baseline
sputum smear varied significantly by M. tuberculosis lineage
(p=0.01), but no significant associations between symptoms or
radiographic findings and lineage were noted. When compared
with patients with disease caused by Euro-American sublineages
other than 724, patients with disease caused by the Indo-Oceanic
Table 1. Distribution of lineages and sublineages of M. tuberculosis isolates obtained from TBTC Study 28 by region and country of
enrollment.
M. tuberculosis lineage
All Study
Participants
African
Region
Participants
Kampala,
Uganda
Durban,
South Africa
Non-African
Region
Participants
North
America
Rio de
Janeiro, Brazil
Barcelona,
Spain
n=306 n=192 n=168 n=24 n=114 n=83 n=20 n=11
Euro-American - other
than 724
145 (47%) 56 (29%) 43 (26%) 13 (54%) 89 (78%) 58 (70%) 20 (100%) 11 (100%)
Euro-American – 724 101 (33%) 99 (52%) 99 (59%) — 2 (1.8%) 2 (2.4%) — —
East-African-Indian 26 (8.5%) 24 (12%) 24 (14%) — 2 (1.8%) 2 (2.4%) — —
East Asian 22 (7.2%) 12 (6.2%) 1 (0.6%) 11 (46%) 10 (8.8%) 10 (12%) — —
Indo-Oceanic 11 (3.6%) 1 (0.5%) 1 (0.6%) — 10 (8.8%) 10 (12%) — —
West African 1 1 (0.3%) — —— 1 (0.9%) 1 (1.2%) — —
doi:10.1371/journal.pone.0010753.t001
Figure 1. Algorithm applied to all M. tuberculosis isolates for the determination of lineage and sublineage.
doi:10.1371/journal.pone.0010753.g001
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baseline sputum smear (OR 0.23, 95% CI 0.06–0.91, p=0.03)
while patients with disease caused by Euro-American sublineage
724 were more likely to present with high bacillary load (OR 1.76,
95% CI 1.01–3.08, p=0.05). After stratifying by region, however,
the overall association was no longer statistically significant
(p=0.09).
Factors associated with positive cultures at week 8
In univariate analysis, two M. tuberculosis lineages were found to
be associated with bacteriologic non-conversion at week 8
(p,0.01). Specifically, both Euro-American sublineage 724 (OR
2.38, 95% CI 1.41–4.01, p,0.01) and East Asian lineage (OR
3.11, 95% CI 1.24–7.79, p=0.02) were significantly associated
with a higher probability of positive week-8 culture when
compared with Euro-American sublineages other than 724
(Table 2). However, adjustment for the risk factors for week-8
culture positivity from the parent study (African region of
enrollment, cavitary disease on initial chest radiograph, high
bacillary load on baseline sputum smear and age) resulted in
lineages no longer being a significant risk factor for bacteriologic
non-conversion at 8 weeks. Recognizing that lineage may lead to
certain tuberculosis disease characteristics, we also performed this
analysis excluding cavitation and bacillary load as covariates, and
again found no association between lineage and week-8 culture
positivity, after adjustment for region of enrollment and age.
Univariate analyses stratified by region of enrollment and
presence of cavitation on baseline chest radiograph were
conducted to identify the contribution of lineage for stratum-
specific differences in week-8 culture status (data not shown).
Overall, lineage was not associated with increased likelihood of
positive week 8 culture within any of the region of enrollment/
presence of cavitation strata. However, the data suggest (with a
wide confidence interval) that among patients enrolled from
African sites who had cavitary tuberculosis, disease caused by East
Asian lineage was associated with increased odds of positive week 8
culture when compared to persons with disease caused by Euro-
American sublineages other than 724 (OR 10.7, 95% CI 1.22–
93.1).
Discussion
In this study, our primary objective was to describe the lineages
and sublineages of isolates of M. tuberculosis from participants in an
international, randomized, tuberculosis treatment trial. Our
secondary objectives included exploring differences in disease
presentation by lineage, and determining whether lineage of the
infecting strain of M. tuberculosis is associated with the likelihood of
bacteriologic culture conversion at 8 weeks as a marker for
response to treatment. Examining isolates from Study 28 provided
an opportunity to address this question in tuberculosis patients
who were well-characterized and in whom treatment and follow-
up was assured in a systematic manner, thus addressing potential
confounders of treatment response.
For our first objective, we found that the most common
genotype was the Euro-American lineage, comprising 80% of
isolates in Study 28. The geographic distribution of sublineages
within the Euro-American lineage and that of other lineages was
unequal. Euro-American sublineage 724 was found primarily in
study participants enrolled in Kampala, Uganda. This finding is in
line with a recent report in which Euro-American sublineage 724
was designated the ‘‘Uganda genotype’’, due to its high prevalence
in patients with tuberculosis in that country, which included,
among others, what was previously known as spoligotype M.
africanum subtype Uganda I and II [15]. In our study, two other
lineages identified with near exclusivity to a site or region: 92%
(24/26) of the isolates belonging to the East-African-Indian lineage
were identified in participants enrolled in Kampala, Uganda, and
91% (10/11) of the isolates belonging to the Indo-Oceanic lineage
were identified in participants enrolled in North American sites.
Table 2. The association between week-8 culture positivity and M. tuberculosis lineage, adjusted for clinical risk factors from the
parent study.
Characteristic
Positive week-8 culture
[n (row %)] Univariate Analysis Multivariate Analysis
p-value OR (95% CI) p-value OR (95% CI)
Moxifloxacin (n=152) 56 (37) 0.19 0.74 (0.47–1.17) 0.23 0.73 (0.43–1.22)
Assignment stratum
Non-African/non-cavitary (n=32) 2 (6.3) 1.00 (ref) 1.00 (ref)
Non-African/cavitary (n=82) 27 (33) ,0.01 7.36 (1.64–33.1) 0.02 5.93 (1.25–28.1)
African/non-cavitary (n=47) 21 (45) ,0.01 12.1 (2.59–56.6) 0.01 7.61 (1.43–40.5)
African/cavitary (n=145) 74 (51) ,0.01 15.6 (3.60–67.8) ,0.01 9.86 (1.99–48.9)
Age at enrollment (per year) * 33 (12) 0.95 1.00 (0.98–1.02) 0.06 1.03 (1.00–1.06)
High bacillary burden on baseline sputum smear (n=205) * 100 (49) ,0.01 3.06 (1.79–5.21) 0.03 2.02 (1.09–3.76)
Days to detection in liquid culture system for baseline specimen * 7.1 (4.8) ,0.01 0.92 (0.87–0.96) 0.02 0.94 (0.90–0.99)
Lineage
Euro-American – other than 724 (n=145) 46 (32) 1.00 (ref) 1.00 (ref)
Euro-American – 724 (n=101) 53 (52) ,0.01 2.38 (1.41–4.01) 0.12 1.70 (0.88–3.30)
East-African-Indian (n=26) 11 (42) 0.29 1.58 (0.67–3.70) 0.91 0.95 (0.35–2.54)
East Asian (n=22) 13 (59) 0.02 3.11 (1.24–7.79) 0.30 1.79 (0.60–5.37)
Indo-Oceanic (n=11) 1 (9.1) 0.15 0.22 (0.03–1.73) 0.27 0.29 (0.03–2.58)
*Mean and standard deviation reported for continuous data.
doi:10.1371/journal.pone.0010753.t002
M. tb Lineage Variability
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Beijing spoligotype family [16,17], were found in equal frequency
by region of enrollment, but in Africa, isolates from this lineage
were mainly identified from participants enrolled in South Africa,
where the East Asian lineage was recently identified as an
emerging genotype [18]. The causes for such lineage-specific
associations with geographic regions are unknown. It has been
suggested that the biogeography of M. tuberculosis strains are linked
to ancient human migrations [1], and that strains may have
adapted to specific human host populations over time [7]. The
causes not withstanding, it is important to recognize that within
the context of a clinical trial conducted across diverse geographic
locations, genotypes of M. tuberculosis varied and that some lineages
and sublineages were exclusive to specific sites.
Our secondary objectives for this study were to explore the
impact of lineage on presentation of disease and response to
treatment in Study 28. We found that the lineage of M. tuberculosis
did not independently influence presentation of disease, nor
response to treatment as measured by week-8 culture status as the
primary endpoint. However, we believe our study is underpow-
ered to definitively assess the relationship between lineage and
treatment response as genotyping information identified a co-
linear relationship between site of enrollment and lineage/
sublineage. In stratified univariate analyses we found that among
patients with cavitary tuberculosis enrolled from African sites,
persons with disease caused by East Asian lineage were more likely
to have a positive week-8 culture when compared to persons with
disease caused by Euro-American sublineages other than 724. This
finding, though exploratory in nature and not statistically
significant, is in line with other recent studies that identified
clinical and epidemiologic consequences of specific host-pathogen
relationships in tuberculosis [7,19,20,21,22]. Gagneux and
colleagues, recently showed that lineages of M. tuberculosis varied
in regard to pathogenicity (defined as the ability of M. tuberculosis to
cause secondary cases), and that this variation was driven in part
by specific relationships between the ethnicity of the host and the
phylogeographic grouping of M. tuberculosis [7]. Thwaites et al
[20], identified an association between the East Asian lineage and
disease progression in tuberculosis meningitis, while Caws et al
[19], found that tuberculosis caused by isolates belonging to the
Euro-American lineage was limited and protective against
disseminated, meningeal tuberculosis in Vietnamese adults. Bur-
man et al, performed an evaluation of the role of host-pathogen
relationships in regard to risk for relapse in a phase 3 treatment
trial and found that patients with tuberculosis caused by strains
from the Beijing family (a member of the East Asian lineage) had a
higher risk for relapse, even after adjustment for factors previously
associated with relapse. Interestingly, the association between
lineage and relapse was found to be even stronger when strains
from the Beijing family caused disease among Asian–Pacific
Islanders [21]. Finally, our data suggesting that disease caused by
East Asian lineage isolates in cavitary, African-region participants
may be less responsive to combination therapy is in line with
another recent report from South Africa that found patients with
disease caused by members of the Beijing family had a lower
likelihood of being successfully treated [22].
Our study has several limitations. First, the hypotheses for the
study were proposed post-hoc. We took advantage of the fact that
M. tuberculosis isolates had been collected and stored from well-
characterized participants in a clinical trial; however, the trial itself
was not designed to test the proposed hypotheses, and our study
was limited by the sample size of Study 28. Second, our primary
endpoint was 2 month culture status, not failure or relapse. In the
study by Burman et al [21], strains belonging to the East Asian
lineage were associated with increased risk of relapse and failure,
but not with delayed conversion at week-8 cultures. Study 28 was a
phase 2 trial and did not follow patients through to relapse. Third,
whereas our clinical, microbiologic and radiographic data were
robust as part of the routine clinical trial data collection process,
we did not have measures of nutritional status or co-existing
parasitic infections that might have influenced severity of disease at
presentation and potentially response to treatment. Fourth,
although there is some evidence that genotype may play a role
in pathogenicity, we do not have tools to confirm that all strains
belonging to a particular lineage will have the same pathogenicity
factors.
In summary, we have shown that within the context of a clinical
trial conducted across diverse geographic locations, genotypes of
M. tuberculosis varied and some lineages and sublineages were
exclusive to specific trial sites. We found interesting lineage-
associated variations in disease presentation and week-8 culture
positivity that were not statistically significant when adjusted for
clinical factors and region of enrollment. This highlights the
importance of examining for other factors that potentially impact
treatment outcomes when evaluating the relationship between
genotype and response to tuberculosis therapy. Additional studies
are needed to definitively determine whether phylogenetic lineage
influences treatment outcomes including failure and risk for
relapse.
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